Medherant | Medherant is creating a sustainable, next-generation transdermal drug delivery patch company that creates value for patients, partners and investors.

Our novel TEPI Patch^® technology offers greater convenience, confidence and comfort for patients.

Enabling precise, consistent drug delivery through solvent-free patch technology designed for optimal skin adhesion and tolerability.

A proprietary transdermal platform adaptable across a broad range of therapeutic areas, such as menopause hormone therapy and pain relief.

Testosterone TEPI Patch^® for Women

Medherant’s lead product is a testosterone patch developed to treat Hypoactive Sexual Desire Disorder (HSDD) in postmenopausal women by increasing testosterone levels to within the normal pre-menopausal range. Unlike existing treatments adapted from male formulations, the TEPI^® Patch is specifically designed for women and delivers a precise, consistent dose via a discreet twice-weekly patch.

News & Events

News & Media

Notice of US patent allowance

September 6, 2024

Preliminary results of clinical study of Medherant’s testosterone patch for post-menopausal women

April 10, 2024

Upcoming events

There are currently no upcoming events.

Improving patient care through innovation in transdermal drug delivery